文献速递银屑病与炎症性皮肤病

银屑病治疗中生物制剂与光疗的效益和成本

Benefits and Costs of Biologics and Phototherapy in Psoriasis Treatment.
PubMed 文献 · JAMA Dermatol · 2026-01-01

该模拟建模研究比较了生物制剂、光疗及阶梯治疗在中重度斑块状银屑病中的疗效、生活质量获益和成本效益。结果显示生物制剂生活质量获益最大,但支付方净支付意愿最低;家庭光疗支付方净支付意愿最高;阶梯治疗以较低系统成本获得类似获益。

要点

  • 生物制剂PASI改善最大,但支付方净支付意愿为负。
  • 家庭光疗支付方净支付意愿最高,成本效益好。
  • 阶梯治疗获益与生物制剂相近且变异小、系统成本低。

核心结论

  • 生物制剂提供最大的生活质量获益,阶梯治疗以较低系统成本获得类似获益且变异更小。
  • 光疗对支付方仍具成本效益,但支付方与患者激励方向不一致。

研究设计与样本

  • 模拟建模研究,纳入50万模拟成人中重度斑块状银屑病患者(PASI≥12)。
  • 使用2013至2025年发表的疗效、成本及PASI与QALY映射估计,分析于2025年7月1日至11月21日进行。

主要发现

  • 平均(SD)PASI下降:生物制剂91.6%(20.1%),光疗71.1%(30.3%),阶梯治疗95.2%(10.8%)。
  • 平均(SD)QALY增益:生物制剂0.24(0.08),光疗0.18(0.09),阶梯治疗0.23(0.06)。
  • 平均(SD)年总成本:生物制剂84 034(0)美元,诊室光疗14 760(0)美元,家庭光疗6 222(0)美元。
  • 平均(SD)自付成本:生物制剂2 000(0)美元,诊室光疗5 004(9 241)美元,家庭光疗1 450(0)美元。
  • 支付方净支付意愿最高为家庭光疗(11 694[9 421]美元),最低为生物制剂(-59 926[7 916]美元);患者净支付意愿均为正,生物制剂最高(22 107[7 916]美元)。

关键数值与推荐

  • PASI评分与QALY映射,QALY货币化按每QALY 100 000美元计算。
  • 敏感性分析考虑risankizumab和adalimumab;支付方偏好adalimumab,患者偏好bimekizumab。

临床怎么用

  • 支付方视角下家庭光疗成本效益最优,可考虑降低其自付费用以改善可及性。
  • 阶梯治疗可减少系统成本且疗效变异小,可作为支付方控制成本的策略。
  • 患者偏好生物制剂,需协调支付政策与患者意愿以平衡可及性与系统可持续性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Phototherapy remains an effective and cost-efficient treatment for psoriasis, yet its use is constrained by coverage policies and the inconvenience of in-office treatment. OBJECTIVE: To compare the efficacy, quality-of-life gains, and cost-effectiveness of biologics, phototherapy, and step-therapy strategies. DESIGN, SETTING, AND PARTICIPANTS: Simulation modeling study in patients with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index [PASI] ≥12) using published estimates of efficacy, costs, and mappings between PASI score and quality-adjusted life-years (QALYs) from 2013 through 2025. Analysis was conducted between July 1 and November 21, 2025. EXPOSURES: One year of treatment with a representative biologic (bimekizumab), narrowband UV-B phototherapy (home or office) or a step-therapy regimen where patients initiated phototherapy for 16 weeks and switched to biologics if PASI90 (an improvement in PASI score of ≥90%) was not achieved, continuing the more effective therapy. MAIN OUTCOMES AND MEASURES: Main outcomes were PASI reductions at 32 weeks, QALYs monetized as $100 000 per QALY, and total treatment costs to payers. Secondary outcomes included out-of-pocket costs and net willingness to pay, defined as monetized QALYs minus costs. Sensitivity analyses considered risankizumab and adalimumab. RESULTS: Among 500 000 simulated adult patients, the mean (SD) baseline PASI value was 20.2 (7.5). Mean (SD) PASI reductions were 91.6% (20.1%) for biologics, 71.1% (30.3%) for phototherapy, and 95.2% (10.8%) for the step-therapy regimen. Mean (SD) reductions were most variable for phototherapy (71.1% [30.3%]) and least variable for step therapy (95.2% [10.8%]). Mean (SD) QALY gains were 0.24 (0.08) for biologics, 0.18 (0.09) for phototherapy, and 0.23 (0.06) for step therapy. Mean (SD) monetized gains were $24 107 ($7916) for biologics, $17 916 ($9421) for phototherapy, and $22 560 ($6324) for step therapy. Mean (SD) annual total costs were $84 034 (0) for biologics, $14 760 (0) for office phototherapy, and $6222 (0) for home phototherapy. Mean (SD) out-of-pocket costs were $2000 (0) for biologics, $5004 ($9241) for office phototherapy, and $1450 (0) for home phototherapy. From the payer perspective, mean (SD) net willingness to pay was highest for home phototherapy ($11 694 [$9421]) and lowest for biologics (-$59 926 [$7916]). For patients, the mean (SD) willingness to pay was positive across all regimens and highest for biologics ($22 107 [$7916]), followed by home phototherapy ($16 466 [$9421]) and office phototherapy ($12 912 [$13 192]). Among biologics, payers preferred adalimumab, whereas patients preferred bimekizumab. CONCLUSIONS AND RELEVANCE: In this study, biologics provided the largest quality-of-life gains, while step-therapy strategies achieved similar benefits with less variability and lower system costs. Phototherapy remained cost-effective for payers. Divergent incentives-payers favoring phototherapy and patients favoring biologics-underscore the need to align coverage, including reduced cost sharing for home phototherapy, to improve access and system sustainability.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Kong EL, Buzney EA. Benefits and Costs of Biologics and Phototherapy in Psoriasis Treatment. JAMA Dermatol. 2026. PMID: 41739454. doi:10.1001/jamadermatol.2025.6193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。